US Patent Issued to Mythic Therapeutics on July 21 for "Anti-DLL3 antibodies and methods of use" (Belgian, American Inventors)

ALEXANDRIA, Va., July 21 -- United States Patent no. 12,686,725, issued on July 21, was assigned to Mythic Therapeutics Inc. (Waltham, Mass.).

"Anti-DLL3 antibodies and methods of use" was invented by Gholamreza Hassanzadeh Ghassabeh (Ghent, Belgium), Lorena Lerner (Andover, Mass.), Sonia Feau (Chestnut Hill, Mass.) and Christophe Queva (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides anti-DLL3 binding constructs, such as anti-DLL3 single domain antibodies, as well as polynucleotide encoding the same. Further provided are multispecific binding constructs comprising the DLL3 binding domains described herein and polynucleotides encoding the same. Methods of produ...